Full-Time

Executive Director

Global Clinical Supply Chain, Oncology

Confirmed live in the last 24 hours

Gilead Sciences

Gilead Sciences

10,001+ employees

Develops and commercializes biopharmaceuticals

Compensation Overview

$281k - $363.7k/yr

+ Bonus + Stock-based long-term incentives

Senior, Expert

Company Historically Provides H1B Sponsorship

San Mateo, CA, USA

In Person

Category
Inventory Management
Supply Chain Management
Operations & Logistics
Required Skills
Risk Management
Development Operations (DevOps)
Requirements
  • 16+ Years of relevant industry experience with BA/BS. OR 14+ Years with MA/MS or MBA PHD or PharmD.
  • Has an expert working knowledge of clinical supply chain best practices and experience working with a GxP environment.
  • Has strong cross-functional, multi-cultural awareness and communication skills to lead in a fast-paced, global company.
  • The candidate must demonstrate hands-on end-to-end clinical supply knowledge and experience with clinical trials in therapeutic area of oncology while maintaining elevated, strategic oversight at portfolio level.
Responsibilities
  • Responsible for leading clinical planning function within an assigned therapeutic area (TA).
  • Provides subject expertise on a diverse portfolio of development programs and different therapeutic modalities including small molecules, biologics and cell gene therapy for Gilead’s global clinical trials.
  • Works internally with members in GCSC and other functions including Development Operations, Clinical Operations and Process Development and Manufacturing (PDM) to develop strategies, meet project deliverables, solve business problems and create competitive advantage.
  • Establishes strategies to ensure uninterrupted clinical supply for the overall development portfolio, including clinical development programs and studies at all phases as well as managed access programs.
  • Leads, develops and manages team, which includes recruitment, onboarding, and succession planning.
  • Drives excellence and accountable for setting clear goals and consistently delivering.
  • Responsible for developing and maintaining a culture of continuous improvement.
  • Champions clinical demand and operation planning (CD&OP) interfacing with leaders from Clinical Operations, PDM sub-teams.
  • Ensures efficient and robust resource allocation for PDM sub-teams and clinical study teams.
  • Partners across several PDM functions and with other enterprise functions to ensure the on time in full (OTIF) delivery of IMP to initiate and resupply clinical studies.
  • Responsible for decision-making and direct the long-term vision of optimal supply chain strategies including labeling and distribution activities.
  • Responsible for risk balancing by allocating work.
  • Responsible for planning SOPs, Work Instructions, business policies and procedures to ensure GxP compliance.
  • Oversees and supports clinical study planners.
  • Serves as the PDM sub-team for RFD assets, lead supply management for first in human (FIH) clinical trials.
  • Drives decision-making at cross-functional teams (ClinOps, PDM sub-teams) supporting the long-term vision.
  • Responsible for the departmental budgeting process – forecasts clinical supply spends, estimates headcount requirements as well as department related expenses (contractors, consultants, recruitment, project expenses, etc.).
  • Leads TA level allocations decisions and influences and negotiate partner performance.
Desired Qualifications
  • Degree in a science-related field; MS, PharmD, or MBA desirable.
  • Strong clinical supply management experience/knowledge in forecasting, demand/supply planning, IRT systems, inventory management, clinical labeling, distribution including cold chain, import/export, reverse logistics, CMC and GXP regulations.
  • Prior experience in complex Oncology trials is highly-preferred.
  • Proven strong and effective collaboration, influencing and negotiation skills to work successfully with internal cross-functional group and external suppliers to meet the aggressive clinical study timeline and patient needs.
  • Possesses experience with clinical blinding practices in global study, from Phase 1 to Late Phase.
  • Possesses expert experience in sourcing and managing comparator drugs and other co-meds for clinical studies, and, in comparator sourcing strategy.
  • Expert knowledge of the FDA GxP standards and regulatory guidance documents such as CFR, Annex 13, EU CTR.
  • Expert in leading through ambiguity, can assess options quickly and efficiently implement the best option in alignment with Gilead's culture and expectations for clinical timelines.
  • Excellent verbal, written and interpersonal communication skills are required. Must have the ability to write clear, concise and error free documents/presentations. Must be a confident communicator and presenter to all organizational levels.
  • Strong computer, database and organizational skills required. ERP, Planning System, and Project management experience is a plus.
  • Ability to effectively manage resources and timelines for multiple teams with studies of different complexities. Ability to lead or manage TA, department level and cross-functional projects.

Gilead Sciences is a biopharmaceutical company that develops and sells medicines for various serious health conditions, including HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular issues. The company focuses on extensive research and development to create new therapies, which are then approved by regulatory authorities before being marketed to healthcare providers, hospitals, and pharmacies. Gilead differentiates itself from competitors through its strong commitment to R&D, maintaining a diverse pipeline of potential treatments, and forming strategic partnerships to enhance its offerings. The company's goal is to improve health equity and access to care globally, working with communities to ensure that its medicines reach those in need.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Simplify Jobs

Simplify's Take

What believers are saying

  • Gilead's oncology navigation grant program enhances its reputation in cancer care.
  • The $11 billion investment is expected to create significant economic value and jobs.
  • Partnerships in innovative cancer treatments position Gilead at the forefront of oncology.

What critics are saying

  • Layoffs and halted expansion plans indicate potential operational challenges in biologics.
  • The $202 million settlement may impact Gilead's financial standing and reputation.
  • Intensifying competition from companies like Amgen pressures Gilead's market performance.

What makes Gilead Sciences unique

  • Gilead's partnership with Kymera focuses on novel cancer treatments using molecular glue degraders.
  • The company invests heavily in R&D, with a $11 billion U.S. investment plan.
  • Gilead's collaborations aim to improve patient outcomes and healthcare access globally.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Company News

Plant Services
Jul 4th, 2025
Factory fallout: Manufacturing plant closures and layoffs from Intel, Hasbro, Johnsonville, and more

According to Fierce Biotech, Gilead Sciences, a pharmaceutical company, is laying off 36 employees as part of a strategic shift that ended plans to expand its biologics facility in Oceanside, California.

Pipeline Review
Jun 26th, 2025
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

Gilead Sciences and Kymera Therapeutics enter into exclusive option and license agreement to develop novel oral molecular glue CDK2 degraders.

24-7 Press Release
Jun 26th, 2025
Gilead Sciences, Inc. proudly Supports Unite for HER's Metastatic Breast Cancer Sustainer Program

PHILADELPHIA, PA, June 26, 2025 /24-7PressRelease/ - Unite for HER (UFH) and Gilead Sciences have partnered to provide a new integrative care program free to Black, Hispanic, and underserved metastatic breast cancer patients in the United States.

BioPharma Dive
Jun 25th, 2025
Kymera adds Gilead as research partner, while advancing new candidate with Sanofi

Gilead and Kymera will develop a molecular glue degrader for breast cancer and other solid tumors.

PR Newswire
Jun 1st, 2025
The Academy Of Oncology Nurse Patient Navigators And Gilead Sciences Partner To Launch Oncology Navigation Grant Program

GAINESVILLE, Fla., June 1, 2025 /PRNewswire/ -- The Academy of Oncology Nurse & Patient Navigators (AONN+) is proud to announce the launch of a groundbreaking grant program in partnership with Gilead Sciences aimed at advancing the field of oncology navigation and enhancing patient outcomes within the healthcare setting. This initiative is designed to support the creation, enhancement, and expansion of innovative tools that optimize efficiency and elevate the critical role of oncology navigators.Following the AONN+ call for grant submissions in April, healthcare leaders across the country responded with creative applications, software solution ideas and healthcare system improvements. AONN+ looks to announce the recipients of the award, valued up to $500,000, in June with project work to begin in the July time frame. The AONN+ grant application process and implementation support for awardees also included help from Amplity, AONN+'s association management partner and strategic collaborator."Through this funding mechanism, AONN+ and Gilead are committed to addressing persistent challenges in cancer care by empowering navigators to play a pivotal role in improving patient access to navigation services, removing barriers to cancer care, and supporting treatment adherence," says Candice Roth, MSN, RN, CENP, Executive Director, AONN+. "Navigator utilization continues to present significant opportunities for optimizing patient outcomes, and this program seeks to provide impactful solutions that directly tie proposed tools to measurable improvements in patient care.""As part of Gilead's Community Cancer Collective, we are proud to partner with AONN+ on this exciting initiative in support of the oncology community," said Darren Tayama, M.D., Vice President, US Medical Affairs, Oncology. "Together, AONN+ and Gilead are advancing the future of cancer care through innovative solutions in oncology navigation."About the Academy of Oncology Nurse & Patient Navigators , Inc